Article Sidebar

PDF
Date Published: 24/10/2021
Abstract Views: 219
Views PDF: 116
DOI: https://doi.org/10.51298/vmj.v506i2.1269
Issue
Vol. 506 No. 2 (2021)
Section
Các bài báo
How to Cite
Thị Hân, P. ., & Văn Tờ, T. . (2021). CLASSIFYING PRIMARY OSTEOSARCOMAS ACCORDING TO 2013 WORLD HEALTH ORGANISATION’S CLASSIFICATION OF TUMOURS OF SOFT TISSUE AND BONE AND EVALUATING RELATIONSHIPS WITH SURVIVAL PROBABILITY. Vietnam Medical Journal, 506(2). https://doi.org/10.51298/vmj.v506i2.1269

CLASSIFYING PRIMARY OSTEOSARCOMAS ACCORDING TO 2013 WORLD HEALTH ORGANISATION’S CLASSIFICATION OF TUMOURS OF SOFT TISSUE AND BONE AND EVALUATING RELATIONSHIPS WITH SURVIVAL PROBABILITY

Phạm Thị Hân1,, Tạ Văn Tờ1,2
1 K Hospital
2 Hanoi Medical University

Main Article Content

Abstract

Objectives: Classifying primary osteosarcomas according to the 2013 World Health Organisation classification of tumours of soft tissue and bone and evaluating relationships with survival probability. Subjects and methods: A retrospective and prospective study was performed in 123 patients with primary osteosarcoma and treated in K hospital. Results: 123 patients with primary osteosarcomas: high-grade subtypes were prominent with the percentage of 98.37% of all. In this group, osteoblastic osteosarcoma was highest with 54.47%. Following by chondroblastic osteosarcoma, fibroblastic osteosarcoma. Low grade osteosarcoma confined to 1,63% (p<0,05). 5 year survival rate was 41,7% (95%CI = 0,33 – 0,54). The relationship between histologic subtypes and survival rates was not statistical significant (p>0,05).

Article Details

Keywords

Primary osteosarcoma, histology subtypes, survival rate

References

1. Ferlay J, Colombet M, Soerjomataram I, Mathers C, Parkin D, Piñeros M, et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. International journal of cancer. 2019;144(8):1941-53.
2. Bridge J, Hogendoorn P, DM C, Bridge JA, CW P, Fletcher CD. WHO classification of tumours of soft tissue and bone: International Agency for Research on Cancer; 2013.
3. Bacci G, Longhi A, Versari M, Mercuri M, Briccoli A, Picci P. Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy: 15‐year experience in 789 patients treated at a single institution. Cancer: Interdisciplinary International Journal of the American Cancer Society. 2006;106(5):1154-61.
4. Ries L. SEER cancer statistics review, 1975-2002. http://seer cancer gov/csr/1975_2002/. 2002.
5. Mirabello L, Troisi RJ, Savage SA. Osteosarcoma incidence and survival rates from 1973 to 2004: data from the Surveillance, Epidemiology, and End Results Program. Cancer: Interdisciplinary International Journal of the American Cancer Society. 2009;115(7):1531-43.
6. Minh VT. Nhận xét về đặc điểm lâm sàng, X quang, mô bệnh học và kết quả điều trị ung thư xương nguyên phát tại bệnh viện K. Hà Nội: Trường Đại học Y Hà Nội; 2000.
7. Công TV. Nghên cứu điều trị sacôm tạo xương giai đoạn II bằng phẫu thuật và hóa chất phác đồ doxorubicin, cisplatin tại Bệnh viện K. Hà Nội: Đại học Y Hà Nội; 2009.
8. Bielack SS, Kempf-Bielack B, Delling Gn, Exner GU, Flege S, Helmke K, et al. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. Journal of clinical oncology. 2002;20(3):776-90.
9. Hauben E, Weeden S, Pringle J, Van Marck E, Hogendoorn P. Does the histological subtype of high-grade central osteosarcoma influence the response to treatment with chemotherapy and does it affect overall survival? A study on 570 patients of two consecutive trials of the European Osteosarcoma Intergroup. European Journal of Cancer. 2002;38(9):1218-25.